Interventional Radiology Management of Advanced Schistosomiasis: State of the Art

Priscila Henriques da Silva; Rômulo Florêncio Tristão dos Santos; Denis Szejnfeld; Gloria Maria Martinez Salazar

doi:10.1055/s-0043-1771313

Digestive Disease Interventions, Inhaltsverzeichnis

Digestive Disease Interventions 2024; 08(01): 37-46
DOI: 10.1055/s-0043-1771313

Review Article

Interventional Radiology Management of Advanced Schistosomiasis: State of the Art

Priscila Henriques da Silva

¹Division of Interventional Radiology, Department of Radiology, Federal University of São Paulo, São Paulo, Brazil

,

Rômulo Florêncio Tristão dos Santos

¹Division of Interventional Radiology, Department of Radiology, Federal University of São Paulo, São Paulo, Brazil

,

Denis Szejnfeld

¹Division of Interventional Radiology, Department of Radiology, Federal University of São Paulo, São Paulo, Brazil

,

Gloria Maria Martinez Salazar

²Division of Vascular Interventional Radiology, Department of Radiology, UNC Chapel Hill, Chapel Hill, North Carolina

› Institutsangaben

Abstract

Advanced schistosomiasis is an infectious disease, endemic in some regions, with long-term implications for patient care. It can be associated with conditions such as portal hypertension, variceal hemorrhage, chronic hepatic encephalopathy, and hepatocellular carcinoma. In this article, an overview of the most recent data about the role of interventional radiology in the management of these conditions will be presented, as well as the authors' experience on interventional management of schistosomiasis patients.

Keywords

interventional radiology - schistosomiasis - portal hypertension - hepatocellular carcinoma

Volltext

Referenzen

References
1 Colley DG, Bustinduy AL, Secor WE, King CH. Human schistosomiasis. Lancet 2014; 383 (9936): 2253-2264
2 Vos T, Afshin A, Aiyar S. et al; GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390 (10100): 1211-1259
3 Warren KS. Schistosomiasis: host-pathogen biology. Rev Infect Dis 1982; 4 (04) 771-775
4 Vennervald BJ, Dunne DW. Morbidity in schistosomiasis: an update. Curr Opin Infect Dis 2004; 17 (05) 439-447
5 Manzella A, Ohtomo K, Monzawa S, Lim JH. Schistosomiasis of the liver. Abdom Imaging 2008; 33 (02) 144-150
6 Bustinduy AL, King CH. , et al. Schistosomiasis. Manson's Tropical Diseases. 23rd ed. Edinburgh: Elsevier; 2013:698–725
7 Strickland GT, Abdel-Warib ME. . Schistosomiasis. In: Strickland GT, ed. Hunter's Tropical Medicine. 7th ed. Philadelphia: WB Saunders; 1991:781–802.
8 Andrade ZA. Pathology of human schistosomiasis. Mem Inst Oswaldo Cruz 1987; 82 (Suppl 4): 17-23
9 Monzawa S, Uchiyama G, Ohtomo K, Araki T. Schistosomiasis japonica of the liver: contrast-enhanced CT findings in 113 patients. AJR Am J Roentgenol 1993; 161 (02) 323-327
10 Yosry A. Schistosomiasis and neoplasia. Contrib Microbiol 2006; 13: 81-100
11 Abdel-Rahim AY. Parasitic infections and hepatic neoplasia. Dig Dis 2001; 19 (04) 288-291
12 Kojiro M, Kakizoe S, Yano H, Tsumagari J, Kenmochi K, Nakashima T. Hepatocellular carcinoma and schistosomiasis japonica. A clinicopathologic study of 59 autopsy cases of hepatocellular carcinoma associated with chronic schistosomiasis japonica. Acta Pathol Jpn 1986; 36 (04) 525-532
13 Richter J. Evolution of schistosomiasis-induced pathology after therapy and interruption of exposure to schistosomes: a review of ultrasonographic studies. Acta Trop 2000; 77 (01) 111-131
14 de Franchis R, Baveno V. Baveno V Faculty. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010; 53 (04) 762-768
15 Groszmann RJ, Garcia-Tsao G, Bosch J. et al; Portal Hypertension Collaborative Group. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005; 353 (21) 2254-2261
16 Wang DW, Qian YN, Liu CY, Shao JM. [A survey of advanced schistosomiasis patients with upper gastrointestinal bleeding]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 1989; 7 (02) 119-121
17 Coelho FF, Perini MV, Kruger JA. et al. Management of variceal hemorrhage: current concepts. Arq Bras Cir Dig 2014; 27 (02) 138-144
18 Merli M, Nicolini G, Angeloni S. et al. Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol 2003; 38 (03) 266-272
19 Bittencourt PL, Farias AQ, Strauss E, Mattos AA. Panel of the 1st Brazilian Consensus of Variceal Bleeding, Brazilian Society of Hepatology. Variceal bleeding: consensus meeting report from the Brazilian Society of Hepatology. Arq Gastroenterol 2010; 47 (02) 202-216
20 Raia S, Mies S, Macedo AL. Surgical treatment of portal hypertension in schistosomiasis. World J Surg 1984; 8 (05) 738-752
21 Ferraz AAB, Lopes EPA, Bacelar TS. et al. Tratamento cirúrgico da hipertensão portal esquistossomótica no hc/UFPE: análise de 131 casos. Rev Col Bras Cir 2000; 27 (05) 332-337
22 Makdissi FF, Herman P, Pugliese V. et al. Long-term results of esophagogastric devascularization and splenectomy associated with endoscopic treatment in schistosomal portal hypertension. World J Surg 2010; 34 (11) 2682-2688
23 Farias AQ, Kassab F, da Rocha EC. et al. Propranolol reduces variceal pressure and wall tension in schistosomiasis presinusoidal portal hypertension. J Gastroenterol Hepatol 2009; 24 (12) 1852-1856
24 Haddad CM, Neto AD, Richieri Tda S. et al. Tratamento cirúrgico da hemorragia aguda por varizes esofagogástricas (Operação de Boerema-Crile Jr). Rev Assoc Med Bras 1975; 21 (03) 81-84
25 Sakai P. [Endoscopic sclerosis of esophageal varices after surgical treatment of portal hypertension in patient with hepatosplenic schistosomiasis]. Arq Gastroenterol 2001; 38 (02) 81-83
26 Petroianu A. [Surgical treatment of portal hypertension in schistosomiasis mansoni]. Rev Soc Bras Med Trop 2003; 36 (02) 253-265
27 Raia S, da Silva LC, Gayotto LC, Forster SC, Fukushima J, Strauss E. Portal hypertension in schistosomiasis: a long-term follow-up of a randomized trial comparing three types of surgery. Hepatology 1994; 20 (02) 398-403
28 D'Amico G, Pagliaro L, Pietrosi G, Tarantino I. Emergency sclerotherapy versus vasoactive drugs for bleeding oesophageal varices in cirrhotic patients. Cochrane Database Syst Rev 2010; 2010 (03) CD002233
29 Corbett C, Mangat K, Olliff S, Tripathi D. The role of transjugular intrahepatic portosystemic stent-shunt (TIPSS) in the management of variceal hemorrhage. Liver Int 2012; 32 (10) 1493-1504
30 Dondelinger RF, El-Kadi MH, Taema M. , et al. TIPS in Egyptian hepatic schistosomiasis. In: Rossi P, Ricci P, Broglia L. Portal Hypertension. Diagnostic Imaging and Imaging-Guided Therapy. Berlin, Heidelberg: Springer; 2000:249–263
31 Deng D, Liao MS, Qin JP, Li XA. Relationship between pre-TIPS hepatic hemodynamics and postoperative incidence of hepatic encephalopathy. Hepatobiliary Pancreat Dis Int 2006; 5 (02) 232-236
32 Kraef C, Arand J, Galaski J. et al. Transjugular intrahepatic portosystemic shunt (TIPS) for primary and secondary prophylaxis of variceal bleeding in hepatic schistosomiasis. Travel Med Infect Dis 2019; 30: 130-132
33 Rosemurgy AS, Frohman HA, Teta AF, Luberice K, Ross SB. Prosthetic H-graft portacaval shunts vs transjugular intrahepatic portasystemic stent shunts: 18-year follow-up of a randomized trial. J Am Coll Surg 2012; 214 (04) 445-453 , discussion 453–455
34 Khanna R, Sarin SK. Non-cirrhotic portal hypertension - diagnosis and management. J Hepatol 2014; 60 (02) 421-441
35 Boyer TD, Haskal ZJ. American Association for the Study of Liver Diseases. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: update 2009. Hepatology 2010; 51 (01) 306
36 Richter J, Bode JG, Blondin D. et al. Severe liver fibrosis caused by Schistosoma mansoni: management and treatment with a transjugular intrahepatic portosystemic shunt. Lancet Infect Dis 2015; 15 (06) 731-737
37 Andersson KL, Chung RT. Hepatic schistosomiasis. Curr Treat Options Gastroenterol 2007; 10 (06) 504-512
38 Liu J, Zhou B, Chen D. et al. Transjugular intrahepatic portosystemic shunt placement in patients with schistosomiasis-induced liver fibrosis. Cardiovasc Intervent Radiol 2019; 42 (12) 1760-1770
39 Nordmann T, Schlabe S, Feldt T. et al. TIPS and splenorenal shunt for complications of portal hypertension in chronic hepatosplenic schistosomiasis - a case series and review of the literature. PLoS Negl Trop Dis 2021; 15 (12) e0010065
40 Strauss E, Valla D. Non-cirrhotic portal hypertension -- concept, diagnosis and clinical management. Clin Res Hepatol Gastroenterol 2014; 38 (05) 564-569
41 de Franchis R, Abraldes JG, Bajaj J. et al; Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol 2015; 63 (03) 743-752
42 Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 2017; 65 (01) 310-335
43 Praktiknjo M, Simón-Talero M, Römer J. et al; Baveno VI-SPSS Group of the Baveno Cooperation. Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. J Hepatol 2020; 72 (06) 1140-1150
44 Lynn AM, Singh S, Congly SE. et al. Embolization of portosystemic shunts for treatment of medically refractory hepatic encephalopathy. Liver Transpl 2016; 22 (06) 723-731
45 Zidi SH, Zanditenas D, Gelu-Siméon M. et al. Treatment of chronic portosystemic encephalopathy in cirrhotic patients by embolization of portosystemic shunts. Liver Int 2007; 27 (10) 1389-1393
46 Laleman W, Simon-Talero M, Maleux G. et al; EASL-CLIF-Consortium. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology 2013; 57 (06) 2448-2457
47 Koconis KG, Singh H, Soares G. Partial splenic embolization in the treatment of patients with portal hypertension: a review of the English language literature. J Vasc Interv Radiol 2007; 18 (04) 463-481
48 Kimura F, Itoh H, Ambiru S. et al. Long-term results of initial and repeated partial splenic embolization for the treatment of chronic idiopathic thrombocytopenic purpura. AJR Am J Roentgenol 2002; 179 (05) 1323-1326
49 Miyazaki M, Itoh H, Kaiho T. et al. Partial splenic embolization for the treatment of chronic idiopathic thrombocytopenic purpura. AJR Am J Roentgenol 1994; 163 (01) 123-126
50 Stanley P, Shen TC. Partial embolization of the spleen in patients with thalassemia. J Vasc Interv Radiol 1995; 6 (01) 137-142
51 Dent D, Alsabrook G, Erickson BA. et al. Blunt splenic injuries: high nonoperative management rate can be achieved with selective embolization. J Trauma 2004; 56 (05) 1063-1067
52 Tajiri T, Onda M, Yoshida H, Mamada Y, Taniai N, Kumazaki T. Long-term hematological and biochemical effects of partial splenic embolization in hepatic cirrhosis. Hepatogastroenterology 2002; 49 (47) 1445-1448
53 Pålsson B, Hallén M, Forsberg AM, Alwmark A. Partial splenic embolization: long-term outcome. Langenbecks Arch Surg 2003; 387 (11-12): 421-426
54 Zannini G, Masciariello S, Pagano G, Sangiuolo P, Zotti G, Iaccarino V. Percutaneous splenic artery occlusion for portal hypertension. A new mechanical technique for hypersplenism. Arch Surg 1983; 118 (08) 897-900
55 Nishida O, Moriyasu F, Nakamura T. et al. Interrelationship between splenic and superior mesenteric venous circulation manifested by transient splenic arterial occlusion using a balloon catheter. Hepatology 1987; 7 (03) 442-446
56 Porter BA, Frey CF, Link DP, Lantz BM, Pimstone NR. Splenic embolization monitored by the video dilution technique. AJR Am J Roentgenol 1983; 141 (05) 1063-1065
57 Yoshida H, Mamada Y, Taniai N. et al. Long-term results of partial splenic artery embolization as supplemental treatment for portal-systemic encephalopathy. Am J Gastroenterol 2005; 100 (01) 43-47
58 Uflacker R, d'Albuquerque LAC, de Oliveira e Silva A, de Freitas JM, Gama-Rodrigues JJ. Embolization to reverse severe recurrent hepatic encephalopathy. Arq Gastroenterol 1988; 25 (Spec No): 21-25
59 Xu RY, Liu B, Lin N. Therapeutic effects of endoscopic variceal ligation combined with partial splenic embolization for portal hypertension. World J Gastroenterol 2004; 10 (07) 1072-1074
60 Khurana S, Dubey ML, Malla N. Association of parasitic infections and cancers. Indian J Med Microbiol 2005; 23 (02) 74-79
61 Palumbo E. Association between schistosomiasis and cancer - a review. Infect Dis Clin Pract 2007; 15: 145-148
62 Kakizoe Y. The influence of Schistosoma mansoni infection on carcinogenesis of mouse livers initiated by N-2-fluorenylacetamide. Kurume Med J 1985; 32 (03) 169-178
63 Toda KS, Kikuchi L, Chagas AL. et al. Hepatocellular carcinoma related to schistosoma mansoni infection: case series and literature review. J Clin Transl Hepatol 2015; 3 (04) 260-264
64 el-Zayadi AR, Badran HM, Barakat EM. et al. Hepatocellular carcinoma in Egypt: a single center study over a decade. World J Gastroenterol 2005; 11 (33) 5193-5198
65 Colecchia A, Scaioli E, Montrone L. et al. Pre-operative liver biopsy in cirrhotic patients with early hepatocellular carcinoma represents a safe and accurate diagnostic tool for tumour grading assessment. J Hepatol 2011; 54 (02) 300-305
66 Gadahadh R, Valenti D, Aljiffry M. et al. Surgery and interventional radiology collaborate on combination therapy in hepatocellular carcinoma. US Gastroenterol Hepatol Rev 2011; (07) 44-49
67 Gervais DA, Goldberg SN, Brown DB, Soulen MC, Millward SF, Rajan DK. Society of Interventional Radiology position statement on percutaneous radiofrequency ablation for the treatment of liver tumors. J Vasc Interv Radiol 2009; 20 (7, Suppl): S342-S347
68 Hasegawa K, Makuuchi M, Takayama T. et al. Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol 2008; 49 (04) 589-594
69 Molla N, AlMenieir N, Simoneau E. et al. The role of interventional radiology in the management of hepatocellular carcinoma. Curr Oncol 2014; 21 (03) e480-e492
70 Permpongkosol S, Nicol TL, Link RE. et al. Differences in ablation size in porcine kidney, liver, and lung after cryoablation using the same ablation protocol. AJR Am J Roentgenol 2007; 188 (04) 1028-1032
71 Permpongkosol S, Nicol TL, Khurana H. et al. Thermal maps around two adjacent cryoprobes creating overlapping ablations in porcine liver, lung, and kidney. J Vasc Interv Radiol 2007; 18 (02) 283-287
72 Huang YZ, Zhou SC, Zhou H, Tong M. Radiofrequency ablation versus cryosurgery ablation for hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology 2013; 60 (125) 1131-1135
73 Llovet JM, Real MI, Montaña X. et al; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359 (9319): 1734-1739
74 Davis CR. Interventional radiological treatment of hepatocellular carcinoma. Cancer Contr 2010; 17 (02) 87-99
75 Lewis AL, Gonzalez MV, Lloyd AW. et al. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 2006; 17 (2, Pt 1): 335-342
76 Salem R, Lewandowski RJ, Kulik L. et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011; 140 (02) 497-507.e2